Global phase 2 test of PD-1 antibody initiated by Baiji Shenzhou

Source: Meitong society 2018-04-11 Baiji Shenzhou (NASDAQ: bgne) is a biomedical company in the commercialization stage, focusing on the development and commercialization of innovative molecular targeting and tumor immune drugs for cancer treatment The company today announced that it is developing a global phase 2 clinical trial of anti-PD-1 antibody tislilizumab for patients with previously treated advanced liver cancer (HCC or liver cancer) to achieve the first patient administration "We have made great progress in the development of tislilizumab and are currently conducting three global phase 3 clinical trials We and our partner, new base, are very excited about the progress we have made, and are excited about tislilizumab's global development opportunities and potential, "said Mr Ou Lei Qiang, founder, CEO and chairman of Baiji Shenzhou This phase 2 multicenter trial was designed to evaluate the efficacy and safety of tislilizumab in patients with previously treated unresectable HCC It plans to recruit about 225 patients from about 75 cancer centers in Greater China (including Taiwan), the United States and Europe Patients will receive 200 mg of tislilizumab every three weeks The primary end point of the trial was the overall response rate (ORR) assessed by the Independent Review Committee (IRC), and the secondary end points included the response duration (DOR), progression free survival (PFS), disease control rate (DCR), clinical benefit rate (CBR), and total survival period (OS) assessed by the IRC Other secondary endpoints included orr, DOR, PFS, DCR, CBR, safety, tolerability, and health-related quality of life assessed by the investigator "I look forward to the clinical trials of tislilizumab in patients with advanced liver cancer, for whom the median survival is usually less than one year Patients who did not benefit from first-line or second-line treatment, or who have lost their initial response to treatment, may respond to tislilizumab We are very pleased to be able to form the cognition of tislilizumab from the HCC patients in the phase I dose expansion trial, "said Professor Zheng Anli (Ph.D., MD), the distinguished professor and Dean of cancer center of National Taiwan University and the main researcher of this trial.